Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Inhibitors & Chemicals

(Rac)-Lys-SMCC-DM1

((Rac)-Lys-Nε-MCC-DM1)

Cat. No.: HY-101982A

(Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1 (HY-101982). Lys-SMCC-DM1 is a linker-payload component that has the potential to inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

2',3'-cGAMP-C2-PPA

Cat. No.: HY-141662

2',3'-cGAMP-C2-PPA (45), A cyclic di-nucleotide, is a **STING** agonist (US20210015941A1). 2',3'-cGAMP-C2-PPA is a **drug-linker conjugate for ADC** that can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acetylene-linker-Val-Cit-PABC-MMAE

(LCB14-0602)

Cat. No.: HY-19812

Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for ADC.

Purity: 95.08
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

AcLys-PABC-VC-Aur0101

Cat. No.: HY-111554

AcLys-PABC-VC-Aur0101 is a **drug-linker conjugate for ADC** (anti-CXCR4 ADC) with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the cleavable linker AcLys-PABC-VC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AcLysValCit-PABC-DMAE-SW-163D

Cat. No.: HY-114325

AcLysValCit-PABC-DMAE-SW-163D is a **drug-linker conjugates for ADC** which consists of a natural bis-intercalator, SW-163D, conjugated via an AcLysValCitPABC-DMAE linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminobenzenesulfonic auristatin E

Cat. No.: HY-145989

Aminobenzenesulfonic auristatin E is a **drug-linker conjugate for ADC** with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminooxy CatB-LXR

Cat. No.: HY-144554

Aminooxy CatB-LXR (compound 10) is a drug-linker conjugates for ADC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AmPEG6C2-Aur0131

Cat. No.: HY-111555

AmPEG6C2-Aur0131 is a **drug-linker conjugate for ADC** (anti-CXCR4 ADC) with potent antitumor activity by using Aur0131 (an auristatin microtubule inhibitor), linked via the non-cleavable linker AmPEG6C2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ1508

(MC-Lys-MMETA)

Cat. No.: HY-128962

AZ1508 is a **drug-linker conjugates for ADC** for the treatment of breast and stomach cancer, and the drug is a tubulin inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azide-PEG4-VC-PAB-Doxorubicin

Cat. No.: HY-136288

Azide-PEG4-VC-PAB-Doxorubicin is a drug-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody drug conjugate (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Azido-PEG4-Val-Cit-PAB-MMAE

Cat. No.: HY-W190943

Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Bi-Mc-VC-PAB-MMAE

Cat. No.: HY-141833

Bi-Mc-VC-PAB-MMAE consists ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate for ADC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCK2R Ligand-Linker Conjugates 1

Cat. No.: HY-128941

CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CL2-SN-38

Cat. No.: HY-126350

CL2-SN-38 is a part of the **antibody drug conjugate (ADC)**, can conjugate with the anti-Trop-2-humanized antibody hRS7. SN-38 is a DNA topoisomerase I inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CL2A-SN-38

Cat. No.: HY-128946

CL2A-SN-38 is a **drug-linker conjugate** composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types.

Purity: 98.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CL2E-SN38

Cat. No.: HY-139909

CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (**ADC**). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CL2E-SN38 TFA

Cat. No.: HY-139909A

CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (**ADC**). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cys-mcMMAD

Cat. No.: HY-15750

Cys-mcMMAD is a drug-linker conjugate for ADC. MMAD is a potent tubulin inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

DBA-DM4

Cat. No.: HY-128960

DBA-DM4 is a **drug-linker conjugate** composed of a potent a tubulin inhibitor DM1 and a linker SPDP to make antibody drug conjugate (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-(PEG)3-VC-PAB-MMAE

Cat. No.: HY-111012

DBCO-(PEG)3-VC-PAB-MMAE is made by MMAE conjugated to DBCO-(PEG)3-vc-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg (1 mg x 5), 10 mg (1 mg x 10), 1 mg

DBCO-(PEG2-VC-PAB-MMAE)2

Cat. No.: HY-126690

DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG4-Ahx-DM1

Cat. No.: HY-136260

DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (**ADC**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG4-GGFG-DX8951

Cat. No.: HY-134723

DBCO-PEG4-GGFG-DX8951 is a **drug-linker conjugate for ADC** with potent antitumor activity by using DX8951 (a DNA topoisomerase I inhibitor), linked via the non-cleavable ADC linker DBCO-PEG4-GGFG.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG4-MMAF

Cat. No.: HY-133492

DBCO-PEG4-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

DBCO-PEG4-VA-PBD

Cat. No.: HY-133433

DBCO-PEG4-VA-PBD is a drug-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via DBCO-PEG4-VA.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

DBCO-PEG4-Val-Cit-PAB-MMAF

Cat. No.: HY-130990

DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG4-VC-PAB-DMEA-PNU-159682

Cat. No.: HY-126691

DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for **ADC**, consists the ADC linker DBCO-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

DBCO-PEG4-VC-PAB-MMAE

Cat. No.: HY-136314

DBCO-PEG4-VC-PAB-MMAE consists a ADC linker (DBCO-PEG4-VC-PAB) and a **tubulin polymerization** inhibitor MMAE (HY-15162). DBCO-PEG4-VC-PAB-MMAE can be used in th e synthesis of antibody-drug c onjugates (**ADC**s).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBM-MMAF

Cat. No.: HY-136287

DBM-MMAF is a drug-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody drug conjugate (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Deruxtecan

Cat. No.: HY-13631E

Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.



Purity: 99.43%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg

Desmethyl Vc-seco-DUBA

Cat. No.: HY-131085

Desmethyl Vc-seco-DUBA consists a cleavable ADC linker (Desmethyl Vc-seco) and a DNA alkylating agent (DUBA). Desmethyl Vc-seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DGN549-C

Cat. No.: HY-136297

DGN549-C consists a cleavable ADC linker valine-alanine (va) and PBD dimer. DGN549 is a novel **DNA-alkylating** cytotoxic payload and can be used in the synthesis of antibody-drug conjugates (**ADC**s).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DGN549-L

Cat. No.: HY-145365

DGN549-L is a DNA alkylator and can be utilized for antibody conjugation at lysine residues. DGN549-L can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DM1-PEG4-DBCO

Cat. No.: HY-136261

DM1-(PEG)4-DBCO is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (**ADC**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DM4-SMCC

Cat. No.: HY-126494

DM4-SMCC is a **drug-linker conjugate for ADC** with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

DM4-SPDP

Cat. No.: HY-126493

DM4-SPDP is a drug-linker conjugate composed of a potent antitubulin agent DM4 and a linker SMCC to make antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Doxorubicin-SMCC

Cat. No.: HY-116063

Doxorubicin-SMCC is a **drug-linker conjugate for ADC**. Doxorubicin-SMCC contains a non-cleavable ADC linker and a DNA topoisomerase II inhibitor Doxorubicin.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FCHFHS-ST7612AA1

Cat. No.: HY-112805

FCHFHS-ST7612AA1 is a part of antibody drug conjugates (**ADCs**) charged with **HDAC** inhibitor by a linker, shows antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-Val-Cit-PAB-Duocarmycin TM

Cat. No.: HY-126532

Fmoc-Val-Cit-PAB-Duocarmycin TM is a **drug-linker conjugate for ADC** by using the antitumor antibiotic, Duocarmycin TM, linked via Fmoc-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg

Fmoc-Val-Cit-PAB-MMAE

Cat. No.: HY-19811

Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

Purity: 95.05%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gemcitabine-O-Si(di-iso)-O-Mc

Cat. No.: HY-130812

Gemcitabine-O-Si(di-iso)-O-Mc is a **drug-linker conjugate for ADC** with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gly3-VC-PAB-MMAE

Cat. No.: HY-131056

Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM

Cat. No.: HY-145663

HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a drug-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lys-Nε-SPDB-DM4

Cat. No.: HY-141596

Lys-Nε-SPDB-DM4 is a **drug-linker conjugate** composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody drug conjugate (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lys-SMCC-DM1

(Lys-Nε-MCC-DM1)

Cat. No.: HY-101982

Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a linker-payload component that has the potential to inhibit tubulin polymerization.Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a human epidermal growth factor receptor 2 (HER2)-targeting ADC with a tubulin polymerization inhibitor DM1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MAC glucuronide phenol-linked SN-38

Cat. No.: HY-128943

MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) drug linker.



Purity: 96.26%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

MAC glucuronide α-hydroxy lactone-linked SN-38

Cat. No.: HY-128942

MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a stabilized lactone MAC glucuronide α-hydroxy lactone-linked SN-38 drug linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAC-VC-PABC-ST7612AA1

Cat. No.: HY-112806

MAC-VC-PABC-ST7612AA1 is a part of antibody drug conjugates (**ADCs**) charged with **HDAC** inhibitor by a linker, shows antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-(CH2)5-Val-Cit-PAB-Eribulin

Cat. No.: HY-139642

Mal-(CH2)5-Val-Cit-PAB-Eribulin is a **drug-linker conjugate for ADC** with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Mal-C2-Gly3-EDA-PNU-159682

Cat. No.: HY-126688

Mal-C2-Gly3-EDA-PNU-159682, a drug-linker conjugate for **ADC**, consists a cleavable ADC linker Mal-C2-Gly3-EDA and a potent ADC cytotoxin PNU-159682.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-C6-α-Amanitin

Cat. No.: HY-126683

Mal-C6-α-Amanitin is a **drug-linker conjugate for ADC** with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6.



Purity: 95.37%
Clinical Data: No Development Reported
Size: 5 mg

MAL-di-EG-Val-Cit-PAB-MMAE

Cat. No.: HY-100567

MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent **tubulin** inhibitor (MMAE).



Purity: 98.92%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MAL-di-EG-Val-Cit-PAB-MMAF

Cat. No.: HY-128711

MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F).



Purity: 98.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Mal-PEG2-VCP-Eribulin

Cat. No.: HY-128870

Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG4-VA-PBD

Cat. No.: HY-126685

Mal-PEG4-VA-PBD is a drug-linker conjugate for **ADC** by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via Mal-PEG4-VA.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Mal-PEG4-VC-PAB-DMEA-PNU-159682

Cat. No.: HY-126687

Mal-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for **ADC**, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA

Cat. No.: HY-126684

Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is a drug-linker conjugate for **ADC** by using the antitumor antibiotic, Duocarmycin SA, linked via Mal-PEG4-VC-PAB-DMEA-Seco.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan

Cat. No.: HY-145399

Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan is a conjugate used to synthesis ADC. Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan comprises topoisomerase inhibitor derivative with a linker for connecting to a ligand unit (extracted from patent US20200306243A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG8-Val-Cit-PAB-MMAE

Cat. No.: HY-141156

Mal-PEG8-Val-Cit-PAB-MMAE is a **drug-linker conjugate for ADC**. Mal-PEG8-Val-Cit-PAB-MMAE contains a cleavable ADC linker and a potent tubulin inhibitor MMAE (HY-15162).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-Phe-C4-VC-PAB-DMEA-PNU-159682

Cat. No.: HY-126689

Mal-Phe-C4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for **ADC**, consists the ADC linker Mal-Phe-C4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-Phe-C4-VC-PAB-MMAE

Cat. No.: HY-126686

Mal-Phe-C4-VC-PAB-MMAE is made by MMAE conjugated to Mal-Phe-C4-VC-PAB linker. Monomethyl auristatin E (MMAE), a potent **tubulin** inhibitor, is a toxin payload in antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mal-VC-PAB-ABAEP-Azonafide

Cat. No.: HY-126692

Mal-VC-PAB-ABAEP-Azonafide is a **drug-linker conjugate for ADC** with with potent antitumor activity by using Azonafide (a cytotoxin), linked via the ADC linker Mal-VC-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-VC-PAB-DM1

Cat. No.: HY-126682

Mal-VC-PAB-DM1 is a **drug-linker conjugate for ADC** with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

MB-VC-MGBA

Cat. No.: HY-136289

MB-VC-MGBA is a drug-linker conjugate for ADC with potent antitumor activity by using MGBA (minor-groove-binding DNA-alkylating agent), linked via the ADC linker MB-VC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Alkyl-Hydrazine Modified MMAF

Cat. No.: HY-128961

MC-Alkyl-Hydrazine Modified MMAF is a **drug-linker conjugate for ADC** with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-betaglucuronide-MMAE-1

Cat. No.: HY-136317

MC-betaglucuronide-MMAE-1 is a **drug-linker conjugate for ADC** with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MC-betaglucuronide-MMAE-2

Cat. No.: HY-136321

MC-betaglucuronide-MMAE-2 is a **drug-linker conjugate for ADC** with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mc-Dexamethasone

Cat. No.: HY-136290

Mc-Dexamethasone is a **drug-linker conjugate for ADC**. Mc-Dexamethasone is made toxin Dexamethasone (HY-14648) conjugated to the non-cleavable MC linker. Dexamethasone is a glucocorticoid receptor agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MC-DM1

Cat. No.: HY-136286

MC-DM1 is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody drug conjugate (ADC).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MC-DOXHZN ((E/Z)-Aldoxorubicin; Doxorubicin(6-maleimidocaproyl)hydrazone)

Cat. No.: HY-16261A

MC-DOXHZN ((E/Z)-Aldoxorubicin) is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-DOXHZN hydrochloride ((E/Z)-Aldoxorubicin hydrochloride; Doxorubicin(6-maleimidocaproyl)hydrazone hydrochloride)

Cat. No.: HY-16261B

MC-DOXHZN ((E/Z)-Aldoxorubicin) hydrochloride is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

MC-GGFG-DX8951

Cat. No.: HY-114233

MC-GGFG-DX8951 is a **drug-linker conjugate for ADC** with antitumor activity by using DX8951 (a DNA topoisomerase I inhibitor), linked via the protease cleavable MC-GGFG linker.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Mc-MMAD

Cat. No.: HY-15740

Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a drug-linker conjugate for ADC.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Mc-MMAE

(Maleimidocaproyl-monomethylauristatin E)

Cat. No.: HY-15741

Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent **tubulin** inhibitor. Mc-MMAE is a drug-linker conjugate for ADC.



Purity: 96.47%
Clinical Data: No Development Reported
Size: 5 mg (1 mg x 5), 10 mg (1 mg x 10), 1 mg

MC-SN38

Cat. No.: HY-136170

MC-SN38 is a drug-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody drug conjugate (ADC).



Purity: 98.65%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

MC-Sq-Cit-PAB-Dolastatin10

Cat. No.: HY-128894

MC-Sq-Cit-PAB-Dolastatin10 is a **drug-linker conjugate for ADC** with potent antitumor activity by using Dolastatin10 (a tubulin polymerization inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Sq-Cit-PAB-Gefitinib

Cat. No.: HY-128893

MC-Sq-Cit-PAB-Gefitinib is a **drug-linker conjugate for ADC** with potent antitumor activity by using Gefitinib (an EGFR tyrosine kinase inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-Auristatin E

Cat. No.: HY-128899

MC-Val-Cit-PAB-Auristatin E is a **drug-linker conjugate for ADC** with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MC-Val-Cit-PAB-carfilzomib iodide

Cat. No.: HY-128903

MC-Val-Cit-PAB-carfilzomib iodide is a **drug-linker conjugate for ADC** with potent antitumor activity by using carfilzomib (an irreversible proteasome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

MC-Val-Cit-PAB-clindamycin

Cat. No.: HY-128907

MC-Val-Cit-PAB-clindamycin is a **drug-linker conjugate for ADC** with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-dimethylDNA31

Cat. No.: HY-128905

MC-Val-Cit-PAB-dimethylDNA31 is a **drug-linker conjugate for ADC** with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-duocarmycin chloride

Cat. No.: HY-128904

MC-Val-Cit-PAB-duocarmycin chloride is a **drug-linker conjugate for ADC** with potent antitumor activity by using Duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MC-Val-Cit-PAB-DX8951

Cat. No.: HY-145929

MC-Val-Cit-PAB-DX8951 is a drug-linker conjugate for ADC. MC-Val-Cit-PAB-DX8951 is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MC-Val-Cit-PAB-Indibulin

Cat. No.: HY-128908

MC-Val-Cit-PAB-Indibulin is a **drug-linker conjugate for ADC** with potent antitumor activity by using Indibulin (an orally applicable inhibitor of tubulin assembly), linked via the ADC linker MC-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MC-Val-Cit-PAB-MMAF

(Vc-MMAF)

Cat. No.: HY-112786

MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a **drug-linker conjugate for ADC** with antitumor activity by using the tubulin inhibitor, MMAF, linked via cathepsin cleavable MC-Val-Cit-PAB.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

MC-Val-Cit-PAB-Retapamulin

Cat. No.: HY-128906

MC-Val-Cit-PAB-Retapamulin is a **drug-linker conjugate for ADC** with potent antitumor activity by using Retapamulin (a ribosome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-rifabutin

Cat. No.: HY-128909

MC-Val-Cit-PAB-rifabutin is a **drug-linker conjugate for ADC** with potent antitumor activity by using rifabutin (an DNA-dependent RNA polymerase inhibitor), linked via the ADC linker MC-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-vinblastine

Cat. No.: HY-128902

MC-Val-Cit-PAB-vinblastine is a **drug-linker conjugate for ADC** with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB.



Purity: 90.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MC-VC(S)-PABQ-Tubulysin M

Cat. No.: HY-128910

MC-VC(S)-PABQ-Tubulysin M is a **drug-linker conjugate for ADC** with potent antitumor activity by using Tubulysin M (a tubulin inhibitor), linked via the ADC linker MC-VC(S)-PABQ.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-VC-PAB-MMAD

Cat. No.: HY-136316

MC-VC-PAB-MMAD is a **drug-linker conjugate for ADC** with potent antitumor activity by using MMAD (a potent tubulin inhibitor), linked via the cleavable ADC linker MC-VC-PAB.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Mc-VC-PAB-SN38

Cat. No.: HY-131057

Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MC-VC-PAB-Tubulysin M

Cat. No.: HY-136313

MC-vc-PAB-Tubulysin M consists a cleavable ADC linker (MC-vc-PAB) and a cytotoxic tubulin inhibitor Tubulysin M (HY-N7053).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-VC-PABC-Aur0101

Cat. No.: HY-128955

MC-VC-PABC-Aur0101 is a **drug-linker conjugate for ADC** with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

MC-VC-PABC-DNA31

Cat. No.: HY-128897

MC-VC-PABC-DNA31 is a **drug-linker conjugate for ADC** with potent antitumor activity by using DNA31 (a potent RNA polymerase inhibitor), linked via the ADC linker MC-VC-PABC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MC-VC-PABC-SP 141

Cat. No.: HY-136320

MC-VC-PABC-SP 141 is a **drug-linker conjugate for ADC** with potent antitumor activity by using SP 141 (a potent MDM2 inhibitor), linked via the cleavable ADC linker MC-VC-PABC.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MCC-DM1

Cat. No.: HY-132250

MCC-DM1 is a drug-Linker Conjugates for ADC such ad Anti-CD22-MCC-DM1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MCC-Modified Daunorubicinol

Cat. No.: HY-128959

Daunorubicinol is a **drug-linker conjugate for ADC** with potent antitumor activity by using Aur0101 (DNA Topoisomerase II inhibitor), linked via the ADC linker.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

McMMAF

(Maleimidocaproyl monomethylauristatin F)

Cat. No.: HY-15578

McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MMAE-SMCC

Cat. No.: HY-135660

MMAE-SMCC is a drug-linker conjugate for ADC. MMAE-SMCC is composed of a potent mitotic and a tubulin inhibitor MMAE and a linker SMCC to make antibody drug conjugate.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Modified MMAF-C5-COOH

Cat. No.: HY-141593

Modified MMAF-C5-COOH is a drug-linker conjugate for ADC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT

Cat. No.: HY-132161

MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a Camptothecin-linker compound extracted from patent WO2019195665A1, example 4-1.
MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a **drug-linker conjugate for antibody-drug conjugate (ADC)**.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT

Cat. No.: HY-145943

MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT is a drug-linker conjugate for antibody-drug conjugate (ADC). MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT has the potential for cancer and autoimmune disease research.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N3-PEG3-vc-PAB-MMAE

Cat. No.: HY-100874

N3-PEG3-vc-PAB-MMAE is a synthesized **drug-linker conjugate for ADC** that incorporates the MMAE (a tubulin inhibitor) and 3-unit PEG linker.
N3-PEG3-vc-PAB-MMAE shows potent antitumor activity.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

N3-PEG4-DYKDDDD-Doxorubicin

Cat. No.: HY-133586

N3-PEG4-DYKDDDD-Doxorubicin is a drug-linker conjugate for ADC with potent antitumor activity by using the cytotoxic anthracycline antibiotic, Doxorubicin, linked via the cleavable linker N3-PEG4-DYKDDDD.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N3-PEG4-YPYDVPDYA-Doxorubicin

Cat. No.: HY-131090

N3-PEG4-YPYDVPDYA-Doxorubicin is a drug-linker conjugate for ADC with potent antitumor activity by using the cytotoxic anthracycline antibiotic, Doxorubicin, linked via the cleavable linker N3-PEG4-YPYDVPDYA.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N3-PEG8-Phe-Lys-PABC-Gefitinib

Cat. No.: HY-131088

N3-PEG8-Phe-Lys-PABC-Gefitinib is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NAMPT inhibitor-linker 1

Cat. No.: HY-112615

NAMPT inhibitor-linker 1 is a drug-linker conjugates for **ADC**, composed of an **NAMPT** inhibitor as a payload, and a linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NAMPT inhibitor-linker 2

Cat. No.: HY-112616

NAMPT inhibitor-linker 2 is a drug-linker conjugates for **ADC**, composed of an **NAMPT** inhibitor as a payload, and a linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nitro-PDS-Tubulysin M

Cat. No.: HY-128896

Nitro-PDS-Tubulysin M is a **drug-linker conjugate for ADC** with potent antitumor activity by using Tubulysin M (a tubulin polymerization inhibitor), linked via the ADC linker Nitro-PDS.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OSu-Glu-VC-PAB-MMAD

Cat. No.: HY-136315

OSu-Glu-VC-PAB-MMAD is a **drug-linker conjugate for ADC** with potent antitumor activity by using MMAD (a potent tubulin inhibitor), linked via the cleavable ADC linker OSu-Glu-VC-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PEG4-aminooxy-MMAF

Cat. No.: HY-128968

PEG4-aminooxy-MMAF is a **drug-linker conjugate for ADC** with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4.



Purity: 97.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PNU-EDA-Gly5

Cat. No.: HY-145078

PNU-EDA-Gly5 is an oligo-glycine linker-payload for ADC synthesis, composed of a DNA topoisomerase I inhibitor PNU-159682 and a linker EDA-Gly5.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSMA-ALB-56

Cat. No.: HY-141536

PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSMA-Val-Cit-PAB-MMAE

Cat. No.: HY-141860

PSMA-Val-Cit-PAB-MMAE is a novel small-molecule PSMA-targeted conjugate based on the monomethyl auristatin E for the chemotherapy of prostate cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rha-PEG3-SMCC

Cat. No.: HY-142740

Rha-PEG3-SMCC (compound 13) is a **drug-linker&n bsp;conjugate for ADC** with ;potent antitumor activity by using SMCC (a protein crosslinker), linked via the noncleavable ADC linker Rha-PEG3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SC-VC-PAB-DM1

Cat. No.: HY-126693

SC-VC-PAB-DM1 is a **drug-linker conjugate for ADC** with with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor) , linked via the ADC linker SC-VC-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SC-VC-PAB-MMAE

Cat. No.: HY-126681

SC-VC-PAB-MMAE is a **drug-linker conjugate for ADC** with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SGD-1910

Cat. No.: HY-101162

SGD-1910 is a **drug-linker conjugate for ADC** by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala.



Purity: 95.06%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SMCC-DM1

(DM1-SMCC)

Cat. No.: HY-101070

SMCC-DM1 (DM1-SMCC) is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody drug conjugate (ADC).



Purity: 98.18%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SN38 NHS ester

Cat. No.: HY-145732

SN38 NHS ester is the NHS ester derivative of SN38. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis. SN38 NHS ester can be used for the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SPB

Cat. No.: HY-104025

SPB is a drug-linker conjugate for ADC with potent anti-inflammatory activity by using Xanthotoxol, linked via the ADC linker.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SPDB-DM4

Cat. No.: HY-12460

SPDB-DM4 is a **drug-linker conjugate for ADC** by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SPP-DM1

Cat. No.: HY-126491

SPP-DM1 is a **drug-linker conjugate for ADC** with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

Sulfo-PDBA-DM4

Cat. No.: HY-128954

Sulfo-PDBA-DM4 is a **drug-linker conjugate** composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody drug conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfo-SPDB-DGN462

Cat. No.: HY-136291

Sulfo-SPDB-DGN462 is a **drug-linker conjugate for ADC**. Sulfo-SPDB-DGN462 consists a toxin DGN462 (HY-101150) conjugated to the cleavable Sulfo-SPDB linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

sulfo-SPDB-DM4

Cat. No.: HY-101141

sulfo-SPDB-DM4 is a **drug-linker conjugate for ADC** by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SuO-Glu-Val-Cit-PAB-MMAE

Cat. No.: HY-130989

SuO-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SuO-Val-Cit-PAB-MMAE

Cat. No.: HY-100566

SuO-Val-Cit-PAB-MMAE is a **drug-linker conjugate for ADC** by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tesirine

(SG3249)

Cat. No.: HY-128952

Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics.



Purity: 97.96%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg

Thalidomide-NH-PEG7

Cat. No.: HY-130648

Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate for **ADC**. Thalidomide-NH-PEG7 can be connected to the ligand for protein by a linker to form PROTAC iRucaparib-AP6, a highly specific PARP1 degrader.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TLR7/8 agonist 4 hydroxy-PEG10-acid

Cat. No.: HY-139018

TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a **drug-linker conjugate for ADC** with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the cleavable ADC linker hydroxy-PEG10-acid (HY-133307).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride

Cat. No.: HY-139018A

TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a **drug-linker conjugate for ADC** with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the cleavable ADC linker hydroxy-PEG10-acid (HY-133307).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Val-Cit-PAB-MMAE

Cat. No.: HY-100374

Val-Cit-PAB-MMAE is a **drug-linker conjugate for ADC**. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent **mitotic** inhibitor by inhibiting tubulin polymerization.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 5 mg (1 mg x 5), 10 mg (1 mg x 10), 1 mg

Vat-Cit-PAB-Monomethyl Dolastatin 10

Cat. No.: HY-126492

Vat-Cit-PAB-Monomethyl Dolastatin 10 is a **drug-linker conjugate for ADC** with potent antitumor activity by using Monomethyl Dolastatin 10 (a potent tubulin inhibitor), linked via the ADC linker Vat-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

Vc-MMAD

Cat. No.: HY-15742

Vc-MMAD consists the ADCs linker (Val-Cit) and potent tubulin inhibitor (MMAD). Vc-MMAD is a drug-linker conjugate for ADC.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 1 mg

Vc-seco-DUBA

(SYD985)

Cat. No.: HY-128957

Vc-seco-DUBA (SYD985) is a **drug-linker conjugate for ADC** with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco.



Purity: 99.80%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

VcMMAE

(MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE)

Cat. No.: HY-15575

VcMMAE (mc-vc-PAB-MMAE) is a **drug-linker conjugate for ADC** with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg (1 mg x 5), 10 mg (1 mg x 10)

VCP-Eribulin

Cat. No.: HY-128871

VCP-Eribulin consists the ADCs linker (VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. VCP-Eribulin is an Eribulin-based drug for antibody conjugates.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vipivotide tetraxetan

(PSMA-617)

Cat. No.: HY-117410

Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen **(PSMA)** inhibitor, with a K_i of 0.37 nM.



Purity: 98.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg